Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach
暂无分享,去创建一个
H. Benjamin | A. Chajut | D. Clark | J. Bishop | Hila Cholakh | W. Westra
[1] A R Feinstein,et al. Observer Variability in the Histopathologic Diagnosis of Lung Cancer1, 2 , 2015 .
[2] C. Bingle. Thyroid transcription factor-1. , 1997, The international journal of biochemistry & cell biology.
[3] J. Whitsett,et al. Nuclear localization domain of thyroid transcription factor-1 in respiratory epithelial cells. , 1997, The Biochemical journal.
[4] Anthony Rhodes,et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.
[5] D. Burstein,et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.
[6] S. Lau,et al. Thyroid Transcription Factor-1: A Review , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[7] G. Elmberger,et al. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma , 2003, British Journal of Cancer.
[8] Y. Yatabe,et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.
[9] A. Gown,et al. p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[10] J. Johansson,et al. Processing of Pulmonary Surfactant Protein B by Napsin and Cathepsin H* , 2004, Journal of Biological Chemistry.
[11] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. A. Robinson,et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.
[13] Yuriy Gusev,et al. Real-time expression profiling of microRNA precursors in human cancer cell lines , 2005, Nucleic acids research.
[14] Isaac Bentwich. Prediction and validation of microRNAs and their targets , 2005, FEBS letters.
[15] T. Stephenson,et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques , 2005, Journal of Clinical Pathology.
[16] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[17] R M Levenson,et al. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.
[18] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[19] D. Zander,et al. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material , 2006, Modern Pathology.
[20] R. Lavker,et al. MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. , 2006, Molecular vision.
[21] K. Jöckel,et al. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. , 2006, Lung cancer.
[22] J. Soria,et al. Targeted therapies in lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] H. Kato,et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor‐1 (TTF‐1) for the identification of pulmonary adenocarcinoma cells in pleural effusions , 2007, Diagnostic cytopathology.
[24] Richard Pazdur,et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.
[25] A. Kargı,et al. The Diagnostic Value of TTF-1, CK 5/6, and p63 Immunostaining in Classification of Lung Carcinomas , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[26] W. Gerald,et al. Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.
[27] R. Aharonov,et al. MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.
[28] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[29] Yariv Yogev,et al. Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.
[30] X. Chen,et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.
[31] H. Asamura,et al. Immunohistochemical expression of TTF‐1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity , 2007, Pathology international.
[32] A. Burny,et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis , 2008, European Respiratory Journal.
[33] Gideon Rechavi,et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Bo Jian,et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.
[35] C. Gomez-Fernandez,et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples , 2009, Cancer.